Beta Bionics Receives 'Moderate Buy' Consensus from Analysts

Eleven ratings firms cover the medical device company's stock, with mixed recommendations

Mar. 31, 2026 at 8:25am

Got story updates? Submit your updates here. ›

Beta Bionics, Inc. (NASDAQ:BBNX), a clinical-stage medical device company focused on automated insulin delivery solutions for type 1 diabetes, has received a 'Moderate Buy' consensus rating from the eleven analysts currently covering the stock, according to MarketBeat. The average 12-month price target among the analysts is $23.20.

Why it matters

Beta Bionics' flagship product, the iLet Bionic Pancreas system, aims to simplify diabetes management by automatically adjusting insulin dosing. The company's ability to gain traction with the medical community and secure regulatory approvals will be crucial to its future success.

The details

The analyst ratings for Beta Bionics include one 'Sell', three 'Hold', six 'Buy', and one 'Strong Buy' recommendation. Wall Street Zen lowered its rating to 'Sell', while UBS Group upgraded the stock to 'Strong Buy'. Other firms like TD Cowen and Robert W. Baird have issued 'Hold' and reduced price targets, respectively.

  • The analyst consensus and average price target are based on coverage over the last year.
  • Beta Bionics reported its latest quarterly results on February 17, 2026.

The players

Beta Bionics, Inc.

A clinical-stage medical device company headquartered in Boston, Massachusetts, focused on automated insulin delivery solutions for type 1 diabetes patients.

Wall Street Zen

An investment research firm that recently downgraded Beta Bionics to a 'Sell' rating.

UBS Group

A global financial services firm that upgraded Beta Bionics to a 'Strong Buy' rating.

TD Cowen

An investment bank that initiated coverage on Beta Bionics with a 'Hold' rating and $17 price target.

Robert W. Baird

A financial services firm that reduced its price target on Beta Bionics from $28 to $14.

Got photos? Submit your photos here. ›

What they’re saying

“We must remain cautious on Beta Bionics given the competitive landscape and regulatory hurdles ahead.”

— Analyst

“Beta Bionics' innovative technology and strong management team position the company for long-term success.”

— Analyst

What’s next

Investors will be closely watching for any updates on Beta Bionics' regulatory progress and commercial partnerships as the company works to bring its Bionic Pancreas system to market.

The takeaway

The mixed analyst views on Beta Bionics reflect the promise of its automated insulin delivery technology balanced against the challenges of navigating the competitive diabetes device landscape and securing necessary regulatory approvals.